Sökning: WFRF:(Foukakis Theodoros) >
Neoadjuvant Trastuz...
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial
-
- Hatschek, Thomas (författare)
- Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden,Karolinska Univ Hosp, Breast Canc Ctr, Stockholm, Sweden.;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Foukakis, Theodoros (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Breast Canc Ctr, Stockholm, Sweden.;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Bjöhle, Judith (författare)
- Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden,Karolinska Univ Hosp, Breast Canc Ctr, Stockholm, Sweden.
-
visa fler...
-
- Lekberg, Tobias (författare)
- Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden,Karolinska Univ Hosp, Breast Canc Ctr, Stockholm, Sweden.
-
- Fredholm, Hanna (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Breast Canc Ctr, Stockholm, Sweden.;Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
-
- Elinder, Ellinor (författare)
- Department of Oncology, South Hospital, Stockholm, Sweden,Soder Sjukhuset, Dept Oncol, Stockholm, Sweden.
-
- Bosch, Ana (författare)
- Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.
-
- Pekar, Gyula (författare)
- Department of Pathology, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Dept Pathol, Lund, Sweden.
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Schiza, Aglaia (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Einbeigi, Zakaria (författare)
- Department of Oncology, Southern Älvsborg Hospital, Borås, Sweden,Southern Alvsborg Hosp, Dept Oncol, Borås, Sweden.
-
- Adra, Jamila (författare)
- Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden,Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.
-
- Andersson, Anne, 1966- (författare)
- Umeå universitet,Onkologi,Umeå Univ Hosp, Dept Radiat Sci, Oncol Unit, Umeå, Sweden.
-
- Carlsson, Lena (författare)
- Department of Oncology, Sundsvall Hospital, Sundsvall, Sweden,Sundsvall Hosp, Dept Oncol, Sundsvall, Sweden.
-
- Dreifaldt, Ann Charlotte, 1964- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Oncology, Örebro University Hospital, Örebro, Sweden,Örebro Univ Hosp, Dept Oncol, Örebro, Sweden.
-
- Isaksson-Friman, Erika (författare)
- Department of Oncology, St Göran Hospital, Stockholm, Sweden,St Goran Hosp, Dept Oncol, Stockholm, Sweden.
-
- Agartz, Susanne (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Azavedo, Edward (författare)
- Department of Radiology, Karolinska University Hospital, Stockholm, Sweden,Karolinska Univ Hosp, Dept Radiol, Stockholm, Sweden.
-
- Grybäck, Per (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Nucl Med, Stockholm, Sweden.
-
- Hellström, Mats (författare)
- Central Trial Office, Clinical Trial Unit, Karolinska University Hospital, Stockholm, Sweden,Karolinska Univ Hosp, Clin Trial Unit, Cent Trial Off, Stockholm, Sweden.
-
- Johansson, Hemming (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Clin Trial Unit, Cent Trial Off, Stockholm, Sweden.
-
- Maes, Claudia (författare)
- Central Trial Office, Clinical Trial Unit, Karolinska University Hospital, Stockholm, Sweden,Karolinska Univ Hosp, Clin Trial Unit, Cent Trial Off, Stockholm, Sweden.
-
- Zerdes, Ioannis (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Hartman, Johan (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Brandberg, Yvonne (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Bergh, Jonas (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Breast Canc Ctr, Stockholm, Sweden.;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
visa färre...
-
Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden Karolinska Univ Hosp, Breast Canc Ctr, Stockholm, Sweden;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden. (creator_code:org_t)
- American Medical Association, 2021
- 2021
- Engelska.
-
Ingår i: JAMA Oncology. - : American Medical Association. - 2374-2437 .- 2374-2445. ; 7:9, s. 1360-1367
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- IMPORTANCE: Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown.OBJECTIVE: To assess pathologic complete response (pCR) to standard neoadjuvant therapy of combination docetaxel, trastuzumab, and pertuzumab (DTP) vs T-DM1 monotherapy in patients with ERBB2 (formerly HER2)-positive breast cancer.DESIGN, SETTING, AND PARTICIPANTS: This randomized phase 2 trial, conducted at 9 sites in Sweden, enrolled 202 patients between December 1, 2014, and October 31, 2018. Participants were 18 years or older, with ERBB2-positive tumors larger than 20 mm and/or verified lymph node metastases. Analysis was performed on an intention-to-treat basis.INTERVENTIONS: Patients were randomized to receive 6 cycles of DTP (standard group) or T-DM1 (investigational group). Crossover was recommended at lack of response or occurrence of intolerable toxic effects. Assessment with fluorine 18-labeled fluorodeoxyglucose (F-18-FDG) positron emission tomography combined with computed tomography (PET-CT) was performed at baseline and after 2 and 6 treatment cycles.MAIN OUTCOME AND MEASURES: Pathologic complete response, defined as ypT0 or Tis ypN0. Secondary end points were clinical and radiologic objective response; event-free survival, invasive disease-free survival, distant disease-free survival, and overall survival; safety; health-related quality of life (HRQoL); functional and biological tumor characteristics; and frequency of breast-conserving surgery.RESULTS: Overall, 202 patients were randomized; 197 (99 women in the standard group [median age, 51 years (range, 26-73 years)] and 98 women in the investigational group [median age, 53 years (range, 28-74 years)]) were evaluable for the primary end point. Pathologic complete response was achieved in 45 patients in the standard group (45.5%; 95% CI 35.4%-55.8%) and 43 patients in the investigational group (43.9%; 95% CI 33.9%-54.3%). The difference was not statistically significant (P = .82). In a subgroup analysis, the pCR rate was higher in hormone receptor-negative tumors than in hormone receptor-positive tumors in both treatment groups (45 of 72 [62.5%] vs 45 of 125 [36.0%]). Three patients in the T-DM1 group experienced progression during therapy. In an exploratory analysis, tumor-infiltrating lymphocytes at 10% or more (median) estimated pCR significantly (odds ratio, 2.76; 95% CI, 1.42-5.36; P = .003). Response evaluation with F-18-FDG PET-CT revealed a relative decrease of maximum standardized uptake value by more than 31.3% (median) was associated with pCR (odds ratio, 6.67, 95% CI, 2.38-20.00; P < .001).CONCLUSIONS AND RELEVANCE: In this study, treatment with standard neoadjuvant combination DTP was equal to T-DM1.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hatschek, Thomas
-
Foukakis, Theodo ...
-
Bjöhle, Judith
-
Lekberg, Tobias
-
Fredholm, Hanna
-
Elinder, Ellinor
-
visa fler...
-
Bosch, Ana
-
Pekar, Gyula
-
Lindman, Henrik
-
Schiza, Aglaia
-
Einbeigi, Zakari ...
-
Adra, Jamila
-
Andersson, Anne, ...
-
Carlsson, Lena
-
Dreifaldt, Ann C ...
-
Isaksson-Friman, ...
-
Agartz, Susanne
-
Azavedo, Edward
-
Grybäck, Per
-
Hellström, Mats
-
Johansson, Hemmi ...
-
Maes, Claudia
-
Zerdes, Ioannis
-
Hartman, Johan
-
Brandberg, Yvonn ...
-
Bergh, Jonas
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
JAMA Oncology
- Av lärosätet
-
Örebro universitet
-
Umeå universitet
-
Karolinska Institutet
-
Uppsala universitet